Source: International Congress 2018 – Novel insights in the basic and translational research on idiopathic interstitial pneumonias
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Simon (Brasília, Brazil), C. Melo-Silva, (Brasília, Brazil), P. Veloso-Junior (Brasília, Brazil), V. Amado (Brasília, Brazil), F. Cavalcante-Neto (Brasília, Brazil), A. Bocca (Brasília, Brazil). The potential use of immunomodulatory peptides from Brazilian scorpion Tityus obscurus as pharmacological therapy for Idiopathic Pulmonary Fibrosis. 3716

Member's Comments

No comment yet.

Related content which might interest you: Preclinical data using a novel porcupine inhibitor demonstrates that inhibition of porcupine is a promising target for the treatment of Idiopathic Pulmonary Fibrosis. Source: International Congress 2019 – Extracellular matrix formation and remodelling in physiology and disease Year: 2019 Late Breaking Abstract - Anti-inflammatory activity of novel transtilbene sulfonamide analogues as potential novel therapeutic agents for inflammatory lung disease Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies Year: 2019 Long-term tolerability of real-life use of antifibrotic agents (AFA) in Idiopathic Pulmonary Fibrosis (IPF) Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Mechanical properties and histology in acute lung injury induced by Crotalus durissus terrificus rattlesnake venom Source: Eur Respir J 2007; 30: Suppl. 51, 143s Year: 2007 Mechanical properties of lung after Tityus serrulatus envenomation in anesthetized mice under mechanical ventilation Source: Eur Respir J 2007; 30: Suppl. 51, 349s Year: 2007 Snake Envenomation by Crotalus durissus terrificus Induces Acute Lung Injury Involving the Activation of Epithelial Cells Source: International Congress 2019 – Involvement of the environment and inflammation in pulmonary remodelling Year: 2019 Impact of an interstitial lung diseases Nurse on the compliance to anti-fibrotic drugs in patients with Idiopathic Pulmonary Fibrosis. Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 The potential role of antimicrobial peptides from wasp as regulators of the fibrotic process in idiopathic pulmonary fibrosis. Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases Year: 2019 IgE-mediated inflammatory response induced by Crotalus durissus venom in mice Source: Virtual Congress 2020 – Effects of environmental exposures on lung pathology Year: 2020 The novel elastase inhibitor BAY 85-8501 provides a new approach in the treatment of pulmonary diseases Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 Azoles therapeutic drug monitoring and fungal antimicrobial resistance in adults with Cystic Fibrosis Source: International Congress 2018 – Latest developments in cystic fibrosis Year: 2018 Effect of microbial communities on antimicrobial drug efficacy and host inflammation in Cystic Fibrosis Source: ERS Lung Science Conference 2019 Year: 2019 PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by inhibition of multiple pro-inflammatory/fibrotic key mediators Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013 In vitro characterization of a novel inhaled PI3Kd inhibitor LAS194223 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Efficacy and safety of AZD5069, a CXCR2 antagonist, in adult bronchiectasis Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 Tissue lesions in rat lungs caused by Crotalus durissus collilineatus venom Source: Virtual Congress 2021 – Molecular pathology and cell biology of pulmonary diseases Year: 2021 Anti-inflammatory therapy for sarcoidosis patients Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Oral delivery of transplastomic plant derived angiotensin converting enzyme2 - a novel approach for pulmonary hypertension therapeutics Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Uridine supplementation exerts anti-inflammatory and anti-fibrotic effects in an animal model of pulmonary fibrosis Source: International Congress 2014 – New and old players in fibrotic lung disease Year: 2014 Tolerability and safety of anti-fibrotic agents for idiopathic pulmonary fibrosis in real world Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017